Cuprina Holdings (Cayman) Limited (NASDAQ: CUPR) announced that its 49‑percent owned associate, Cuprina MENA Co. Ltd, has received official product classification from the Saudi Food and Drug Authority (SFDA) for MEDIFLY, the company’s medical‑grade maggot debridement therapy. The SFDA classified MEDIFLY as a Medical Device–Drug combination product, placing the primary mode of action under the medical device framework.
The classification removes a key regulatory barrier and allows Cuprina to complete the remaining scientific and technical requirements needed to launch MEDIFLY across Saudi Arabia’s healthcare network. Saudi Arabia’s chronic‑wound patient population represents a sizable market, and the approval aligns with Cuprina’s strategy to expand its presence in the Middle East and North Africa.
The announcement coincides with the appointment of Dr. Enming Yong to Cuprina’s Medical and Scientific Advisory Board. Dr. Yong is a consultant in endocrinology at Tan Tock Seng Hospital and an adjunct senior lecturer at the Lee Kong Chian School of Medicine. His expertise in diabetic limb salvage, vascular access, and wound care, including maggot debridement therapy, is expected to strengthen the company’s clinical governance and support the development of evidence‑based protocols.
Cuprina’s financial performance remains challenging. For the six months ended June 30 2025, revenue was $18,040, a 40 % decline year‑over‑year, and the company reported a net loss of $1,528,121. In FY 2024, the company posted earnings of –$1.1 million on revenue of $37.14 k, a 63.14 % year‑over‑year drop. Negative margins, a Piotroski F‑Score of 2, and a Nasdaq non‑compliance notice for failing to meet the $1.00 minimum bid price underscore the company’s financial headwinds.
CEO David Quek Yong Qi said, 'The first quarter of 2026 has been defined by focused execution and the strengthening of our scientific foundation. Securing our regulatory classification for MEDIFLY in Saudi Arabia provides a clear commercial roadmap for the MENA region, but equally vital is the elevation of our clinical governance.' He added, 'The appointment of Dr. Yong is a transformative step for Cuprina; his profound expertise in endocrinology and leadership within Singapore’s public healthcare ecosystem will be instrumental as we refine our scientific protocols and scale our evidence‑based solutions globally. Dr. Yong’s oversight ensures that our innovation remains deeply rooted in patient safety and clinical excellence as we address the global challenge of chronic wound care.'
While the regulatory milestone and board appointment signal progress toward expanding MEDIFLY’s commercial footprint, the company’s ongoing financial challenges and Nasdaq compliance issues suggest that investors will weigh the potential upside against significant headwinds.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.